Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

Heather Whitaker; Beth Findlay; Jana Zitha; Rosalind Goudie; Katie Hassell; Josie Evans; Panoraia Kalapotharakou; Utkarsh Agrawal; Beatrix Kele; Mark Hamilton; Catherine Moore; Rachel Byford; Julia Stowe; Chris Robertson; Anastasia Couzens; Gavin Jamie; Katja Hoschler; Kathleen Pheasant; Elizabeth Button; Catherine Quinot; Tim Jones; Sneha Anand; Conall Watson; Nick Andrews; Simon de Lusignan; Maria Zambon; Christopher Williams; Simon Cottrell; Kimberly Marsh; Jim McMenamin; Jamie Lopez Bernal

doi:10.1111/irv.13284

Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

Heather Whitaker, Beth Findlay, Jana Zitha, Rosalind Goudie, Katie Hassell, Josie Evans, Panoraia Kalapotharakou, Utkarsh Agrawal, Beatrix Kele, Mark Hamilton, Catherine Moore, Rachel Byford, Julia Stowe, Chris Robertson, Anastasia Couzens, Gavin Jamie, Katja Hoschler, Kathleen Pheasant, Elizabeth Button, Catherine QuinotTim Jones, Sneha Anand, Conall Watson, Nick Andrews, Simon de Lusignan, Maria Zambon, Christopher Williams, Simon Cottrell, Kimberly Marsh, Jim McMenamin, Jamie Lopez Bernal^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

10 Downloads (Pure)

Abstract

Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England. Methods: A test negative design was used to estimate vaccine effectiveness. Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over. Conclusions: During a period of co‐circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

Original language	English
Article number	e13284
Number of pages	6
Journal	Influenza and Other Respiratory Viruses
Volume	18
Issue number	5
DOIs	https://doi.org/10.1111/irv.13284
Publication status	Published - 21 May 2024

Funding

UK Health Security Agency, Public Health Scotland and Public Health Wales

Keywords

hospitalisation
effectiveness
vaccine
influenza

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/irv.13284Licence: CC BY 4.0

Whitaker-etal-IORV-2024-Interim-2023-2024-season-influenza-vaccine-effectiveness-in-primary-and-secondary-careFinal published version, 230 KBLicence: CC BY 4.0

Cite this

Whitaker, H., Findlay, B., Zitha, J., Goudie, R., Hassell, K., Evans, J., Kalapotharakou, P., Agrawal, U., Kele, B., Hamilton, M., Moore, C., Byford, R., Stowe, J., Robertson, C., Couzens, A., Jamie, G., Hoschler, K., Pheasant, K., Button, E., ... Lopez Bernal, J. (2024). Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom. Influenza and Other Respiratory Viruses , 18(5), Article e13284. https://doi.org/10.1111/irv.13284

@article{bd438a3f06c44a23a1c2334acb7a1dda,

title = "Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom",

abstract = "Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England. Methods: A test negative design was used to estimate vaccine effectiveness. Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over. Conclusions: During a period of co‐circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.",

keywords = "hospitalisation, effectiveness, vaccine, influenza",

author = "Heather Whitaker and Beth Findlay and Jana Zitha and Rosalind Goudie and Katie Hassell and Josie Evans and Panoraia Kalapotharakou and Utkarsh Agrawal and Beatrix Kele and Mark Hamilton and Catherine Moore and Rachel Byford and Julia Stowe and Chris Robertson and Anastasia Couzens and Gavin Jamie and Katja Hoschler and Kathleen Pheasant and Elizabeth Button and Catherine Quinot and Tim Jones and Sneha Anand and Conall Watson and Nick Andrews and {de Lusignan}, Simon and Maria Zambon and Christopher Williams and Simon Cottrell and Kimberly Marsh and Jim McMenamin and Jamie Lopez Bernal",

year = "2024",

month = may,

day = "21",

doi = "10.1111/irv.13284",

language = "English",

volume = "18",

journal = "Influenza and Other Respiratory Viruses ",

issn = "1750-2640",

publisher = "Wiley-Blackwell",

number = "5",

}

Whitaker, H, Findlay, B, Zitha, J, Goudie, R, Hassell, K, Evans, J, Kalapotharakou, P, Agrawal, U, Kele, B, Hamilton, M, Moore, C, Byford, R, Stowe, J, Robertson, C, Couzens, A, Jamie, G, Hoschler, K, Pheasant, K, Button, E, Quinot, C, Jones, T, Anand, S, Watson, C, Andrews, N, de Lusignan, S, Zambon, M, Williams, C, Cottrell, S, Marsh, K, McMenamin, J & Lopez Bernal, J 2024, 'Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom', Influenza and Other Respiratory Viruses , vol. 18, no. 5, e13284. https://doi.org/10.1111/irv.13284

TY - JOUR

T1 - Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

AU - Whitaker, Heather

AU - Findlay, Beth

AU - Zitha, Jana

AU - Goudie, Rosalind

AU - Hassell, Katie

AU - Evans, Josie

AU - Kalapotharakou, Panoraia

AU - Agrawal, Utkarsh

AU - Kele, Beatrix

AU - Hamilton, Mark

AU - Moore, Catherine

AU - Byford, Rachel

AU - Stowe, Julia

AU - Robertson, Chris

AU - Couzens, Anastasia

AU - Jamie, Gavin

AU - Hoschler, Katja

AU - Pheasant, Kathleen

AU - Button, Elizabeth

AU - Quinot, Catherine

AU - Jones, Tim

AU - Anand, Sneha

AU - Watson, Conall

AU - Andrews, Nick

AU - de Lusignan, Simon

AU - Zambon, Maria

AU - Williams, Christopher

AU - Cottrell, Simon

AU - Marsh, Kimberly

AU - McMenamin, Jim

AU - Lopez Bernal, Jamie

PY - 2024/5/21

Y1 - 2024/5/21

N2 - Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England. Methods: A test negative design was used to estimate vaccine effectiveness. Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over. Conclusions: During a period of co‐circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

AB - Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England. Methods: A test negative design was used to estimate vaccine effectiveness. Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over. Conclusions: During a period of co‐circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

KW - hospitalisation

KW - effectiveness

KW - vaccine

KW - influenza

U2 - 10.1111/irv.13284

DO - 10.1111/irv.13284

M3 - Article

SN - 1750-2640

VL - 18

JO - Influenza and Other Respiratory Viruses

JF - Influenza and Other Respiratory Viruses

IS - 5

M1 - e13284

ER -

Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

Abstract

Funding

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this